Major jolt for Indian pharma as Trump unveils phased 200% tariff on generic drugs

US President Donald Trump has announced a phased tariff plan on imported generic medicines, a move that could significantly impact India's pharmaceutical exports to the US.

Generic drugs will face zero tariff for the next two years, followed by a 100% tariff for one year and then a 200% tariff thereafter.

India supplies nearly 40% of all generic medicines used in the US, with annual exports worth $9-10 billion, making the announcement a major concern for the country's pharma industry.

(This is a Breaking News copy. Further details awaited.)